Souheil Abou Assi, MD
Gastroenterology · Richmond, VANPI 1023004710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 609 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 32.9% of the total.
Across 609 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$908
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$820
- QOL Medical, LLC$750
- Sanofi$430
- plus $2K from 30 others
Across 2 payments — averaging $4175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8K
What the payments were for
- Food & beverage$9,99699%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 222 | $3,314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 115 | $1,575 |
| Johnson & Johnson | 55 | $908 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 45 | $820 |
| QOL Medical, LLC | 32 | $750 |
| Sanofi | 16 | $430 |
| Bristol Myers Squibb | 24 | $317 |
| Pfizer | 14 | $241 |
| Ardelyx, Inc. | 11 | $197 |
| Phathom Pharmaceuticals, Inc. | 10 | $167 |
| Ironwood Pharmaceuticals, Inc | 6 | $132 |
| Ipsen Biopharmaceuticals, Inc | 4 | $118 |
| Ferring Pharmaceuticals Inc. | 6 | $94 |
| Vivus LLC | 5 | $92 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Braintree Laboratories, Inc. | 4 | $82 |
| Intercept Pharmaceuticals, Inc. | 3 | $73 |
| Celltrion USA Inc. | 2 | $61 |
| Organon | 3 | $60 |
| Nestle Healthcare Nutrition Inc. | 4 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Concordia Pharmaceuticals Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Biocon Biologics Inc | 2 | $49 |
| Lilly USA, LLC | 2 | $43 |
| Apollo Endosurgery US Inc | 2 | $38 |
| W. L. Gore & Associates, Inc. | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Amgen | 1 | $29 |
| Boston Scientific | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Enterra Medical, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Olympus America Inc. | 1 | $14 |
| ERBE USA Inc | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $13 |
How this compares
$10,068 in reported general payments places this provider in the 80th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $646,205 |
| Mesalamine | 44 | $41,730 |
| CreonLipase/Protease/Amylase | 13 | $36,237 |
| LinzessLinaclotide | 16 | $18,799 |
| Dexlansoprazole DrDexlansoprazole | 31 | $13,340 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 114 | $7,410 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 17 | $2,909 |
| Mesalamine ErMesalamine | 28 | $2,749 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 168 | $2,466 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 15 | $2,433 |
| Pantoprazole Sodium | 252 | $2,371 |
| Famotidine | 165 | $1,803 |
| Dicyclomine Hcl | 106 | $1,799 |
| Omeprazole | 122 | $1,386 |
| Budesonide DrBudesonide | 13 | $1,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $908 | $646,20522 claims |
| AbbVieCreon, Linzess | $3,314 | $55,03729 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $94 | $2,90917 claims |
| Braintree Laboratories, Inc.Sutab | $82 | $2,43315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Richmond
- Arun SanyalRichmond$855K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
- Jasmohan BajajRichmond$72K
- Binu JohnRichmond$33K
- Arthi SanjeeviRichmond$22K
- Henry EllettRichmond$22K
- Ray KeateRichmond$22K
- Tilak ShahRichmond$20K
- Joseph SpataroRichmond$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.